Related Experiment Videos

A case of hereditary angioneurotic edema associated with systemic lupus erythematosus

Insights

Hereditary angioneurotic edema (HANE) is linked to C1 inhibitor deficiency, which can trigger systemic lupus erythematosus (SLE)-like symptoms. Treatment with methylprednisolone improved C1 inhibitor levels and clinical outcomes in a patient with HANE and SLE.

Area of Science:

  • Immunology
  • Genetics
  • Rheumatology

Background:

  • Hereditary angioneurotic edema (HANE) is a rare genetic disorder characterized by recurrent episodes of severe swelling.
  • C1 inhibitor (C1 INH) deficiency is the primary cause of HANE, leading to dysregulation of the complement system.
  • Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with diverse clinical manifestations.

Observation:

  • A family presented with a pedigree of C1 inhibitor deficiency, with some members exhibiting idiopathic edema characteristic of HANE.
  • The proband, initially diagnosed with HANE, later developed serological and hematological indices consistent with definite SLE, including positive LE cell, elevated DNA antibodies, antinuclear factor (ANF), and nephropathy.
  • Despite the absence of idiopathic edema, the proband had low C1 INH levels and lack of complement hemolytic activity (CH50).

Findings:

  • The proband's clinical course suggests SLE developed secondary to a hereditary deficiency in a complement component (C1 INH).
  • Elevated levels of anti-virus antibodies were observed, consistent with the hypothesis that complement deficiencies predispose individuals to viral infections, potentially triggering SLE-like disease.
  • Treatment with methylprednisolone normalized C1 INH levels and ameliorated the proband's clinical symptoms.

Implications:

  • This case highlights a potential link between C1 inhibitor deficiency and the development of SLE, suggesting complement deficiencies can unmask or trigger autoimmune conditions.
  • The findings support the hypothesis that recurrent infections, facilitated by complement deficiencies, may play a role in the pathogenesis of SLE-like diseases.
  • Methylprednisolone therapy shows promise in managing both HANE and associated SLE-like manifestations by restoring C1 INH levels.

Related Concept Videos